20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
- Edesa Biotech Inc (NASDAQ:EDSA) announced preliminary topline results from a Phase 2b study evaluating multiple concentrations of the company's drug candidate, EB01, as monotherapy for moderate-to-severe chronic Allergic Contact Dermatitis.
- EB01 is a non-steroidal anti-inflamamatory compound that inhibits secretory phospholipase 2.
- Edesa reported that 1.0% EB01 cream demonstrated statistically significant improvement over the placebo.
- For the primary endpoint, patients with 1.0% EB01-treated lesions demonstrated a 60% average improvement in symptoms from baseline versus 39% for placebo/vehicle.
- The effect was also observed at 15 days (44% for 1.0% EB01 vs. 29% for placebo) and continued at follow-up (64% for 1.0% EB01 vs. 44% for placebo).
- For the secondary efficacy endpoint, 53% of patients with 1.0% EB01-treated lesions achieved a score of "clear" or "almost clear," with at least a 2-point improvement from baseline. Only 29% of patients in the placebo group reached the same endpoint.
- No serious treatment-related adverse events were reported across all concentrations. The 2.0% and 0.2% formulations did not show significant differences compared to the placebo.
- The company expects to complete the Phase 2b data analysis by midyear.
- Price Action: EDSA shares are down 39.88% at $1.51 on the last check Tuesday.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine." A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!